VUSION
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VUSION (VUSION).
Antifungal; inhibits fungal squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell membrane synthesis.
| Metabolism | Not systemically absorbed; minimal hepatic metabolism via CYP enzymes if absorbed. |
| Excretion | Primarily eliminated via biliary/fecal route; minimal renal excretion (<5% unchanged). Approximately 80% of the absorbed dose appears in feces as unchanged drug and metabolites. |
| Half-life | Terminal elimination half-life is approximately 36 hours, reflecting prolonged exposure in stratum corneum and hair follicles; systemic half-life is negligible due to minimal percutaneous absorption. |
| Protein binding | Due to minimal systemic absorption, protein binding data not clinically relevant; in vitro studies suggest >90% bound to plasma proteins (primarily albumin) at systemic concentrations achieved. |
| Volume of Distribution | Not established due to negligible systemic absorption; percutaneous absorption estimated <0.5% of applied dose, so Vd is not clinically meaningful. |
| Bioavailability | Percutaneous absorption is <0.5% of the applied dose; systemic bioavailability is negligible (<1%). |
| Onset of Action | Clinical effect (reduction in erythema, scaling, and pruritus) observed within 2–4 weeks of twice-daily application; onset not defined for systemic effects as absorption is minimal. |
| Duration of Action | Duration of action after discontinuation is not defined; treatment typically continued for 4 weeks. If no improvement, alternative therapy should be considered. Relapse may occur if treatment stopped prematurely. |
| Molecular Weight | 416.4 |
Apply a thin layer to the affected area twice daily (morning and evening) for 7 days. Topical use only.
| Dosage form | OINTMENT |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | For infants aged 5 weeks to 12 months, apply a thin layer to the affected area twice daily for 7 days. |
| Geriatric use | No specific dosage adjustment required; use caution due to potential for increased skin sensitivity. |
| 1st trimester | No adequate studies in pregnant women. Should be used during first trimester only if potential benefit justifies potential risk to fetus. |
| 2nd trimester | Animal studies have shown no evidence of fetal harm. Use only if clearly needed. |
| 3rd trimester | Safety in third trimester has not been established. Avoid use near term due to possible effects on neonatal skin. |
Clinical note
Comprehensive clinical and safety monograph for VUSION (VUSION).
| Placental transfer | Unknown; molecular weight suggests potential for placental transfer, but no data available. |
| Breastfeeding | It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when administered to a nursing woman. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to any component of the product
| Precautions | For external use only, Avoid contact with eyes, nose, mouth, or other mucous membranes, Discontinue if irritation or sensitization occurs, Not for ophthalmic or vaginal use |
| Food/Dietary | No known food interactions. |
| Clinical Pearls | VUSION (0.25% zinc oxide and 0.15% undecylenic acid ointment) is used for diaper dermatitis. Avoid contact with eyes. Apply to clean, dry skin at each diaper change. Not for use on broken skin or if infection is present. |
Loading safety data…
| Lactation Rating |
| L3 (Moderately Safe) or 'Unknown risk' |
| Teratogenic Risk | No teratogenic effects reported in animal studies; human data insufficient. First trimester: unknown risk; second/third trimester: low systemic absorption likely negligible. Use only if clearly needed. |
| Fetal Monitoring | No specific fetal monitoring required. Monitor for local skin reactions at application site. Assess for signs of maternal irritation or hypersensitivity. |
| Fertility Effects | No adverse effects on fertility reported in animal studies. Human data insufficient. Unlikely to impact fertility due to minimal systemic absorption. |
| Patient Advice | Apply a thin layer to the affected area at each diaper change. · Clean and dry the area thoroughly before application. · Do not use on broken skin or if signs of infection (e.g., pus, oozing) appear. · Stop use and consult doctor if condition worsens or persists for more than 7 days. · Keep out of eyes and mouth. |